Expanding Product Portfolio Crescita Therapeutics is actively acquiring assets, such as the recent $900K purchase from bankruptcy proceedings, which indicates an increasing product and market expansion strategy. Sales teams can target new customer segments and retail channels emerging from these acquisitions.

Innovative Delivery Technologies With proprietary drug delivery platforms like MMPE and DuraPeel, Crescita offers advanced topical formulations. Opportunities exist to promote these technologies to dermatology professionals, pharmaceutical companies, and cosmetic brands seeking enhanced skin absorption solutions.

Focus on Skincare and Pain The company's portfolio includes both non-prescription skincare and prescription pain treatments, opening cross-selling opportunities across healthcare providers, pharmacies, and clinics that cater to skin conditions or pain management needs.

Market Entry in Cannabis Sector Crescita is developing topical formulations for cannabis and hemp using its patented technologies, presenting a new avenue for sales in the growing natural and medical cannabis markets, appealing to consumers and medical practitioners interested in alternative therapies.

Growing Mid-Sized Company With a workforce of up to 200 employees and revenues ranging between 10M and 50M, Crescita is positioned as a mid-sized player, suitable for partnering with suppliers, distributors, and collaborators looking to scale innovative dermatological and pharmaceutical products.